Better-than-expected Q1 21; full-year guidance maintained
06/05/21 -"Benefiting from the strong uptake of the subcutaneous formulation and continued market share gain across lines, Darzalex reported better-than-expected sales in Q1 21 with the ex-US region leading the ..."
Pages
49
Language
English
Published on
06/05/21
You may also be interested by these reports :
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...
16/04/24
Preview: Positive 1Q24 driven by clinical developments of portfolio companies
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
15/04/24
Turnaround story on track – TP increased to CHF 30.00 (from CHF 25.00) – Add reiterated